FDA Asks: Thoughts on Paperwork for Rare Animal Meds?
Published Date: 2/20/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about new animal drugs for less common animals and uses. This helps make sure these drugs are safe and effective without causing extra paperwork headaches. If you’re involved with these drugs, you’ve got until April 21, 2026, to share your comments—no cost, just your voice!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
7‑Year Exclusivity for MUMS Sponsors
If you sponsor a designated Minor Use or Minor Species (MUMS) new animal drug, the designation makes you eligible for incentives including a 7‑year period of exclusive marketing rights. The designation is optional but the FDA uses sponsor submissions to determine eligibility for these benefits.
Indexing Lets Some Unapproved Drugs Be Marketed
FDA rules let certain unapproved new animal drugs for minor species be added to an Index so they can be legally marketed for those species. The indexing program is intended to make more medications legally available to veterinarians and animal owners for treatment of minor species.
Estimated Paperwork Burden on Sponsors
FDA estimates the total annual reporting burden for this information collection is 5,562 hours and the total annual recordkeeping burden is 80 hours. FDA reports an overall increase of 60 hours and a corresponding increase of 120 responses and records compared with prior estimates.
Annual Reports, eSubmitter, and Recordkeeping Rules
Sponsors of MUMS‑designated drugs must demonstrate “due diligence” by submitting annual reports documenting progress for each designation and may use FDA's eSubmitter system (access requires a previously established account). Qualified expert panel leaders must keep written reports and related notes for 2 years, and holders of indexed drugs must maintain records of safety or effectiveness information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20663, Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations
The FDA wants your thoughts on how they collect info about food products that might have tiny amounts of banned or changed pesticides. This affects farmers, food sellers, and anyone handling these foods, making sure safety rules keep up with new pesticide limits. You’ve got until December 7, 2026, to share your views—no cost, just your voice!
Previous / Next Documents
Previous: 2026-03352, Agency Information Collection Activities; Proposed Collection; Comment Request; Adverse Events Associated With New Animal Drugs
The FDA wants your thoughts on how it collects reports about problems with new animal drugs and manufacturing issues. This affects drug makers, vets, and pet owners who help spot side effects in animals. Comments are open until April 21, 2026, so jump in now to help shape safer animal medicines without adding extra costs or delays.
Next: 2026-03355, Presidential Declaration Amendment of a Major Disaster for Public Assistance Only for the State of Tennessee
The President has updated the disaster declaration for Tennessee after a severe winter storm in late January 2026. Now, four more counties—Lawrence, Maury, Robertson, and Wilson—can get public assistance to help recover. If you’re affected, you have until April 7 to apply for physical damage loans and until November 6 for economic injury loans.